This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Allogeneic hematopoietic cell transplantation in patients ⩾70 years: which patients may benefit?
Blood Cancer Journal Open Access 08 July 2016
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005; 106: 2912–2919.
Gratwohl A, Hermans J, Goldman JM, Arcese W, Carreras E, Devergie A et al. Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Lancet 1998; 352: 1087–1092.
Versluis J, Labopin M, Niederwieser D, Socie G, Schlenk RF, Milpied N et al. Prediction of non-relapse mortality in recipients of reduced intensity conditioning allogeneic stem cell transplantation with AML in first complete remission. Leukemia 2014; 29: 51–57.
Valcárcel D, Martino R, Caballero D, Martin J, Ferra C, Nieto JB et al. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival. J Clin Oncol 2008; 26: 577–584.
Piñana JL, Martino R, Barba P, Margall N, Roig MC, Valcárcel D et al. Cytomegalovirus infection and disease after reduced intensity conditioning allogeneic stem cell transplantation: single-centre experience. Bone Marrow Transplant 2010; 45: 534–542.
Martino R, Piñana JL, Parody R, Valcarcel D, Sureda A, Brunet S et al. Lower respiratory tract respiratory virus infections increase the risk of invasive aspergillosis after a reduced-intensity allogeneic hematopoietic SCT. Bone Marrow Transplant 2009; 44: 749–756.
Sorror ML . How I assess comorbidities before hematopoietic cell transplantation. Blood 2013; 121: 2854–2863.
Iacobelli S . Suggestions on the use of statistical methodologies in studies of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 2013; 48: S1–37.
Kaplan EL, Meier P . Non parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457–481.
Harrell FE Jr, Lee KL, Califf RM, Pryor DB, Rosati RA . Regression modelling strategies for improved prognostic prediction. Stat Med 1984; 3: 143–152.
Barba P, Martino R, Pérez-Simón JA, Fernández-Avilés F, Castillo N, Piñana JL et al. Combination of the hematopoietic cell transplantation comorbidity index and the European Group for Blood and Marrow Transplantation score allows a better stratification of high-risk patients undergoing reduced-toxicity allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2014; 20: 66–72.
ElSawy M, Storer BE, Sorror ML . To combine or not to combine: optimizing risk assessment before allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2014; 20: 1455–1456.
Barba P, Piñana JL, Martino R, Valcárcel D, Amorós A, Sureda A et al. Comparison of two pretransplant predictive models and a flexible HCT-CI using different cut off points to determine low-, intermediate-, and high-risk groups: the flexible HCT-CI is the best predictor of NRM and OS in a population of patients undergoing allo-RIC. Biol Blood Marrow Transplant 2010; 16: 413–420.
Xhaard A, Porcher R, Chien JW, de Latour RP, Robin M, Ribaud P et al. Impact of comorbidity indexes on non-relapse mortality. Leukemia 2008; 22: 2062–2069.
Acknowledgements
This work was funded by Instituto de Salud Carlos III, Spain (PI1100872, RD06/0020/0101, RD12/0036/0071, EC07/90065), Pla Recerca de Catalunya (2009-SGR-168), Marató TV3 (100830/31/32) and Fundacion Cellex, Spain, to JS.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Barba, P., Martino, R., Orti, G. et al. Validation of a new integrated prognostic score to predict non-relapse mortality in patients undergoing reduced-intensity conditioning allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 50, 1371–1374 (2015). https://doi.org/10.1038/bmt.2015.144
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2015.144
This article is cited by
-
Allogeneic hematopoietic cell transplantation in patients ⩾70 years: which patients may benefit?
Blood Cancer Journal (2016)